Vyome Holdings (HIND) Change in Accured Expenses (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Change in Accured Expenses of -$278628.0 for Q1 2026, down 509.62% year-over-year from $68021.0 in Q1 2025, and down 228.96% quarter-over-quarter from $216052.0 in Q4 2025.
Vyome Holdings (HIND) Change in Accured Expenses (2015 - 2026) Analysis & Trends
Vyome Holdings' Change in Accured Expenses history runs 12 years deep, the most recent figure standing at -$278628.0 for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 509.62% year-over-year to -$278628.0; the TTM figure through Mar 2026 stood at -$146098.0 (down 154.48% YoY), while the FY2025 annual figure was $200551.0, up 440.72% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$278628.0, down from $216052.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $1.5 million in Q2 2022, with the low at -$3.2 million in Q2 2023.
- The 5-year median for Change in Accured Expenses is $69000.0 (2023), against an average of -$185055.2.
- The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses surged 371.75% in 2024, then slumped 1023.87% in 2025.
- Vyome Holdings' Change in Accured Expenses stood at $499000.0 in 2022, then sank by 238.88% to -$693000.0 in 2023, then jumped by 66.18% to -$234371.0 in 2024, then surged by 192.18% to $216052.0 in 2025, then sank by 228.96% to -$278628.0 in 2026.
- Business Quant data shows HIND's Change in Accured Expenses at -$278628.0 in Q1 2026, $216052.0 in Q4 2025, and $923499.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | -95,880.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -95,880.00 |
| Jun 30, 2026 | -95,880.00 |
| Mar 31, 2026 | -278,628.00 |
| Mar 31, 2026 | -278,628.00 |
| Dec 31, 2025 | 216,052.00 |
| Dec 31, 2025 | 216,052.00 |
| Sep 30, 2025 | 923,499.00 |
| Sep 30, 2025 | 923,499.00 |
| Jun 30, 2025 | -1.01 Mn |
| Jun 30, 2025 | -1.01 Mn |
| Mar 31, 2025 | 68,021.00 |
| Mar 31, 2025 | 68,021.00 |
| Dec 31, 2024 | -234,371.00 |
| Dec 31, 2024 | -234,371.00 |
| Sep 30, 2024 | 325,510.00 |
| Sep 30, 2024 | 325,510.00 |
| Jun 30, 2024 | 109,000.00 |
| Jun 30, 2024 | 109,000.00 |
| Mar 31, 2024 | -259,000.00 |
| Mar 31, 2024 | -259,000.00 |